Company SkinBioTherapeutics plc

Equities

SBTX

GB00BF33H870

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

Delayed London S.E. Other stock markets 10:30:43 08/05/2024 BST			5-day change	1st Jan Change
8.94 ^GBX	-3.35%		-3.35%	-41.38%

04-05	SkinBioTherapeutics Gets Bond Conversion Notice from Macquarie	MT
03-22	SkinBioTherapeutics half-year revenue jumps on UK-based sales	AN

SkinBioTherapeutics plc is a United Kingdom-based life science company, which is focused on skin health. The principal activity of the Company is that of research and development focused on harnessing the microbiome for human health. The Companyâs segments include UK, US, and EU. The Company's platform technology, SkinBiotix, applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company is targeting five specific skin healthcare sectors, such as cosmetics skincare, food supplements for the treatment of skin conditions, medical skin care, infection control in both the home and the hospital environment, and pharmaceuticals for the prescribed treatment of skin conditions. The Company's product, AxisBiotix-Ps, is a food supplement to address the symptoms of mild to moderate psoriasis. The Company is also focused on the application of SkinBiotix technology in the treatment of various classes of skin wounds.

Number of employees: 11

GBP in Million	2022	Weight	2023	Weight	Delta
Human Microbiome Research 100.0 %	0	100.0 %	0	100.0 %	+76.64%

GBP in Million	2022	Weight	Weight	Delta
United Kingdom 90.1 %	0	77.2 %	90.1 %	+106.15%
United states 7.0 %	0	22.8 %	7.0 %	-45.68%
European Union 2.9 %	-	-	2.9 %	-

Managers	Title	Age	Since
Stuart Ashman CEO	Chief Executive Officer	-	17/04/19
Manprit Randhawa DFI	Director of Finance/CFO	41	31/05/22
Stephen France COO	Chief Operating Officer	-	-
Catherine O'Neill CTO	Chief Tech/Sci/R&D Officer	-	-
Melissa Greenwell AUD	Comptroller/Controller/Auditor	-	28/02/23

Members of the board	Title	Age	Since
Catherine Prescott BRD	Director/Board Member	-	28/02/17
Martin Hunt CHM	Chairman	66	02/10/16
Stuart Ashman CEO	Chief Executive Officer	-	17/04/19
Catherine O'Neill CTO	Chief Tech/Sci/R&D Officer	-	-
Danielle Bekker BRD	Director/Board Member	47	26/04/22

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	200,379,907	160,808,554 ( 80.25 %)	0	80.25 %

Name	Equities	%	Valuation
OPTIBIOTIX HEALTH PLC 12.94 %	24,940,639	12.94 %	4 M p
Seneca Partners Ltd. 7.553 %	14,562,764	7.553 %	2 M p
Yarra Investment Management Ltd. 7.168 %	13,820,349	7.168 %	2 M p
Odd Asset Management Ltd. 6.829 %	13,165,553	6.829 %	2 M p
The University of Manchester 4.147 %	7,995,243	4.147 %	1 M p
Unicorn Asset Management Ltd. 4.095 %	7,894,736	4.095 %	1 M p
Catherine O'Neill 2.443 %	4,710,233	2.443 %	758 630 p
Hygea VCT Plc (Private Equity) 1.416 %	2,730,710	1.416 %	439 808 p
Evelyn Partners Investment Management LLP 1.198 %	2,309,421	1.198 %	371 955 p
Evelyn Partners Fund Solutions Ltd. 0.7565 %	1,458,512	0.7565 %	234 908 p

SkinBioTherapeutics Plc

Newcastle Helix The Core

NE4 5TF, Newcastle-upon-Tyne

+44 19 1495 7325

http://www.skinbiotherapeutics.com

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
SKINBIOTHERAPEUTICS PLC	-41.38%	22.37M
REGENERON PHARMACEUTICALS, INC.	+10.44%	107B
VERTEX PHARMACEUTICALS INCORPORATED	+0.82%	106B
ARGENX SE	+9.00%	23.47B
BIONTECH SE	-13.89%	21.9B
GENMAB A/S	-6.08%	18.77B
WUXI APPTEC CO., LTD.	-37.26%	17.85B
BEIGENE, LTD.	-10.98%	16.78B
NEUROCRINE BIOSCIENCES, INC.	+8.67%	14.41B
SAREPTA THERAPEUTICS, INC.	+41.08%	12.86B

Bio Therapeutic Drugs